Skip to content

About Us
Product Pipeline
Marketed Products

News

Contact Us

Stay up to date with our latest research
and corporate developments

Latest News & Media

News

2018/3/8

A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.

TaiRx, Inc. (6580) announces today that its new injection product, Zelnite®, received NDA approval f…
[Read More]
2017/10/31

TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.

Lee WJ, Chen YL, Chu YW, Chien DS. Comparison of glutathione peroxidase-3 protein expression and enz…
[Read More]
2017/8/22

TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.

TaiRx Announces License Agreement with Northwestern University and Ann & Robert H. Lurie Childre…
[Read More]
2017/6/15

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.

TaiRx shows its potential in new cancer drug development and will be listed on the emerging stock ma…
[Read More]

←Previous Page

1 2 3 4 5 6 7

Facebook
Link
YouTube
Instagram

Copyright© 2026 TaiRx, inc.